RIVAROXABAN | A208534 | DR REDDYS LABORATORIES LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Bayer Pharma AG, et al. v. Dr. Reddy's Laboratories, Inc. et al. 1 patentANDA 208534rivaroxaban | D. Del. | 2025-08-19 | Terminated 2025-12-10 | — |
Bayer Pharma AG et al v. Dr. Reddys Laboratories, Ltd. et al 1 patentANDA 208534rivaroxaban | D. Del. | 2021-05-24 | Terminated 2025-12-23 | — |
BAYER INTELLECTUAL PROPERTY GMBH et al v. DR. REDDY'S LABORATORIES, LTD. et al 1 patentANDA 208534rivaroxaban | D.N.J. | 2020-08-12 | Terminated 2020-11-04 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.7967
per ea
Lowest NADAC/Unit
$0.7967
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 43598098118RIVAROXABAN 2.5 MG TABLET | $0.7967 | EA | Generic | — | 2026-06-17 |
| 43598098160RIVAROXABAN 2.5 MG TABLET | $0.7967 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.